(a) LS mean change in PANSS score from baseline in patients receiving placebo, low-dose lurasidone, or lurasidone 74 mg or 148 mg (combined data); (b) LS mean change in PANSS score in ER and ENR who remained on 74 mg lurasidone or switched to 148 mg lurasidone [Loebel et al. 2016]. Adapted with permission from Physicians Postgraduate Press, Inc.
BL, baseline; ENR, early nonresponders; ER, early responders; LS, least square means; PANSS, Positive and Negative Syndrome Scale.